The New Economics of Population Genomics

Population genetics research has reached a turning point. For years, scientists relied on microarrays to identify disease-linked genetic variants. However, these tools suffer from significant limitations, most notably an ancestry bias that favors European populations while leaving Asian and other groups underrepresented. This creates a data gap that stalls the accuracy of medical research and drug development.

Twist Bioscience is shifting this landscape by replacing legacy array technology with next-generation sequencing, or NGS, tools designed for population-scale studies. Their approach includes the FlexPrep UHT Library Preparation Kit, which removes the need for individual sample concentration and quantification. By automating these steps through Normalization by Ligation technology, labs can process thousands of samples in a single run. This transition allows researchers to decrease labor, reduce plastic waste, and maintain higher sequencing output.

Practical applications demonstrate clear gains. Gene by Gene, a firm based in the United States, migrated its entire volume to an NGS-based workflow to manage increasing demand. By integrating these new tools, the company doubled its output without increasing headcount, while shutting down 40 incubators previously required for legacy methods. The ability to tune sequencing depth by sample provides researchers with granular control, moving beyond the fixed nature of older arrays.

For large-scale cohort studies, the company offers specific tools like the Human 600k Genotyping Panel. This provides an ethnicity-neutral alternative to standard arrays, capturing broader context around genetic targets to discover novel variants. When paired with customization options, researchers can target specific genomic regions tailored to the needs of different communities.

Building equitable genomic databases requires high-quality data and high-speed, cost-effective operations. As global initiatives work to include diverse populations, the move away from legacy methods toward automated, scalable NGS workflows is critical. This change ensures that genomic insights remain relevant for the global population rather than just a segment of it.